Molecular structure of Nifuroxazide, CAS Number: 965-52-6
Nifuroxazide (CAS 965-52-6)
See product citations (5)
Alternate Names:
5-Nitro-2-furaldehyde p-hydroxybenzoylhydrazone
Application:
Nifuroxazide is an inhibitor of STAT activation and signaling activity
CAS Number:
965-52-6
Purity:
>97%
Molecular Weight:
275.22
Molecular Formula:
C12H9N3O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Nifuroxazide is a nitrofuran compound inhibitor of STAT transcription factor signaling. Nifuroxazide is described to block constitutive phosphorylation of STAT3 by reducing Jak kinase autophosphorylation, decreasing the viability of myeloma cells depending on constitutive STAT3 activity for survival while not affecting normal peripheral blood mononuclear cells. Nifuroxazide produces decreases in tyrosine phosphorylation of Jak2 and Tyk2, and showed no effects on EGF receptor tyrosine kinase or Src kinase, indicating a relative specificity of Nifuroxazide for Jak2 and Tyk2. Nifuroxazide shows no inhibition of Akt or MAPK phosphorylation.
Nifuroxazide (CAS 965-52-6) References
- Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. | Nelson, EA., et al. 2008. Blood. 112: 5095-102. PMID: 18824601
- Residue depletion of nifuroxazide in broiler chicken. | Gao, F., et al. 2013. J Sci Food Agric. 93: 2172-8. PMID: 23339038
- Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. | Yang, F., et al. 2015. Cell Death Dis. 6: e1701. PMID: 25811798
- Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. | Zhu, Y., et al. 2016. Sci Rep. 6: 20253. PMID: 26830149
- Nifuroxazide, a STAT3 inhibitor, mitigates inflammatory burden and protects against diabetes-induced nephropathy in rats. | Said, E., et al. 2018. Chem Biol Interact. 281: 111-120. PMID: 29291386
- Nifuroxazide induces apoptosis, inhibits cell migration and invasion in osteosarcoma. | Luo, Y., et al. 2019. Invest New Drugs. 37: 1006-1013. PMID: 30680584
- Pro-Nifuroxazide Self-Assembly Leads to Triggerable Nanomedicine for Anti-cancer Therapy. | Misra, SK., et al. 2019. ACS Appl Mater Interfaces. 11: 18074-18089. PMID: 31013055
- Nifuroxazide Mitigates Angiogenesis in Ehlrich's Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling. | El-Sherbiny, M., et al. 2021. Molecules. 26: PMID: 34833950
- Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study. | Gan, C., et al. 2022. Respir Res. 23: 32. PMID: 35172837
- Nifuroxazide-loaded cubosomes exhibit an advancement in pulmonary delivery and attenuate bleomycin-induced lung fibrosis by regulating the STAT3 and NF-κB signaling: A new challenge for unmet therapeutic needs. | Saber, S., et al. 2022. Biomed Pharmacother. 148: 112731. PMID: 35220029
- Nifuroxazide in combination with CpG ODN exerts greater efficacy against hepatocellular carcinoma. | Wang, Y., et al. 2022. Int Immunopharmacol. 108: 108911. PMID: 35729838
- Nifuroxazide modulates hepatic expression of LXRs/SR-BI/CES1/CYP7A1 and LDL-R and attenuates experimentally-induced hypercholesterolemia and the associated cardiovascular complications. | Hasson, TS., et al. 2022. Life Sci. 306: 120790. PMID: 35817168
- Pimitespib, an HSP90 inhibitor, augments nifuroxazide-induced disruption in the IL-6/STAT3/HIF-1α autocrine loop in rats with bleomycin-challenged lungs: Evolutionary perspective in managing pulmonary fibrosis. | El-Kashef, DH., et al. 2022. Biomed Pharmacother. 153: 113487. PMID: 36076505
- Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer. | Li, C., et al. 2023. Mol Cancer Ther. 22: 306-316. PMID: 36622760
- Nifuroxazide inhibits the growth of glioblastoma and promotes the infiltration of CD8 T cells to enhance antitumour immunity. | Wang, X., et al. 2023. Int Immunopharmacol. 118: 109987. PMID: 36924564
Inhibitor of:
C-MIP, EG435337, IFN-α1, IFN-δ, IL-6Rα, LIF, LIFR, Sall4, Stat1, Stat3, Stat5, Stat5b, TIAR, and Tyrosine Kinase.Activator of:
IL-10Rβ, Selenoprotein O, and SOCS-2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nifuroxazide, 500 mg | sc-204128 | 500 mg | $199.00 | |||
Nifuroxazide, 5 g | sc-204128A | 5 g | $510.00 |